Stock & Company Details
Actinium Pharmaceuticals Inc $ATNM
Price:
46,691,331
31M
$31M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
0.00
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
ATNM technical indicators
Latest Actinium Pharmaceuticals Inc (ATNM) technical indicators as of 2026-06-30: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
38.81 2.6%
MACD:
-0.05 1.8%
SMA 50:
$1.16 0.5%
SMA 200:
$1.29 0.3%
EMA 20:
$1.04 0.6%
Bollinger Bands:
1.16 / 0.91
Stochastic:
26.91 29.8%
ADX 14:
16.16 3.9%
ATR 14:
0.06 1.3%
CCI 20:
-95.50 21.1%
OBV:
-3.79M 3.9%
ROC 12:
-5.77% 1.0%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Finance Bot
Ask your questions
Start by typing a question below.
